ClinicalTrials.gg
CompletedNCT04712110Updated Jun 6, 2023Results posted

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

A Phase 1/2 interventional study of TAK-019 and Placebo in Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), sponsored by Takeda. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Takeda · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.

At the first visit, the study doctor will check if each person can take part. Those who can take part will be chosen for 1 of 2 treatments by chance. Participants will either receive an injection of TAK-019 or a placebo in their arm. In this study, a placebo will look like the TAK-019 vaccine but will not have any medicine in it. 3 times as many participants will receive TAK-019 than placebo. Participants will receive 2 injections of TAK-019 or placebo, 21 days apart.

Participants will be asked to record their temperature and any medical problems in an electronic diary for up to 7 days after each injection.

During the study, participants will visit the clinic for regular check-ups, blood tests, and sometimes for nose swab samples. When all participants have attended a clinic visit 28 days after their 2nd injection, the study sponsor (Takeda) will check how many participants have made enough antibodies to protect them against Covid-19.

The participants will stay in the study for up to 12 months after they have had their 2nd injection. During this time, the study doctors will continue to check how many participants have made enough antibodies to protect them against Covid-19. Also, they will check if participants have any more side effects from TAK-019 or the placebo.

Read the detailed description

The drug being tested in this study is called TAK-019. TAK-019 is being tested to prevent infectious disease caused by Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2). This study will look at the evaluate the safety and immunogenicity of 2 doses of TAK-019 by intramuscular (IM) injection 21 days apart in healthy Japanese male and female adults.

The study will enroll approximately 200 healthy volunteers. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • TAK-019 0.5 mL
  • Placebo- this is an injection that looks like the study drug but has no active ingredient

All participants will be asked to take intramuscular injection in the upper arm twice throughout the study.

This multi-center trial will be conducted in Japan. The overall time to participate in this study is 12 months from the second vaccination (totally 387 days). Participants will make multiple visits to the clinic and will be contacted by telephone or a final visit after the last vaccination for a follow-up assessment.

02

Conditions studied

  • Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
03

In context

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

This study's enrollment of 200 is above the median of 140 across 210 interventional studies indexed under Severe Acute Respiratory Syndrome.

Browse Severe Acute Respiratory Syndrome studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Japanese male and female adult participants aged >= 20 years of age at the time of signing of .
  2. Participants who understand and are willing to comply with trial procedures and are available for the duration of follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received any other SARS-CoV-2 or other experimental novel coronavirus vaccine prior to the trial.
  2. Participants who have close contact of anyone known to have COVID-19 within 30 days prior to the trial vaccination.
  3. Participants who were tested positive for SARS-CoV-2 prior to the trial or before the trial vaccination.
  4. Participants who are on current treatment with other agents for prophylaxis of COVID-19.
  5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.
  6. Participants with a active infection (as assessed by the Investigator) or oral temperature >= 38 degree Celsius within 3 days of the intended date of vaccination.
  7. Participants with known or allergy to any of the investigational vaccine components.
  8. Participants with history or any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose additional risk to the participants due to participation in the trial.
  9. Participants with known or suspected impairment/alteration of immune function, including history of any disease or neuro-inflammatory disease.
  10. Abnormalities of splenic or thymic function.
  11. Participants with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
  12. Participants with any serious chronic or progressive disease (eg, neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
  13. Participants with (BMI) greater than or equal to 30 kg/m\^2 (BMI= weight in kg/ height in meters\^2).
  14. Participants participating in any clinical trial with another investigational product within 30 days prior to the trial vaccination or intend to participate in another clinical trial at any time during the conduct of this trial.
  15. Participants who received or plan to receive any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to trial dose administration.
  16. Participants with acute or chronic clinically significant disease including pulmonary, cardiovascular, hepatic or renal abnormality evaluated by physical examination.
  17. Participants involved in the trial conduct or their first degree relatives.
  18. Participants who have history or infection of , , and infection.
  19. Female participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    TAK-019

    TAK-019 0.5 mL, intramuscular injection in the upper arm

    Biological: TAK-019

  • Placebo comparator
    Placebo

    TAK-019 Matching Placebo, intramuscular injection in the upper arm

    Biological: Placebo

Interventions

  • BiologicalTAK-019

    TAK-019 intramuscular injection

  • BiologicalPlacebo

    Placebo intramuscular injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination

    Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.

    Time frame: Up to Day 7 (6 subsequent days after first vaccination on Day 1)

  2. Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination

    Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.

    Time frame: Up to Day 28 (6 subsequent days after second vaccination on Day 22)

  3. Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination

    Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.

    Time frame: Up to Day 7 (6 subsequent days after first vaccination on Day 1)

  4. Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination

    Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.

    Time frame: Up to Day 28 (6 subsequent days after second vaccination on Day 22)

  5. Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination

    Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.

    Time frame: Up to Day 21 (20 days after first vaccination on Day 1)

  6. Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination

    Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.

    Time frame: Up to Day 49 (27 days after second vaccination on Day 22)

  7. Percentage of Participants With Serious Adverse Events (SAEs) Until Day 50

    Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this outcome measure (OM) and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs until Day 50 were reported in this outcome measure.

    Time frame: Day 1 up to Day 50

  8. Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50

    AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESIs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs until Day 50 were reported in this outcome measure.

    Time frame: Day 1 up to Day 50

  9. Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50

    MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs until Day 50 were reported in this outcome measure.

    Time frame: Day 1 up to Day 50

  10. Percentage of Participants With Any AE Leading to Discontinuation of Vaccination

    Only any unsolicited AE leading to discontinuation of vaccination data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to discontinuation of vaccination was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to discontinuation of vaccination until Day 22 were reported in this outcome measure.

    Time frame: Day 1 up to Day 22

  11. Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50

    Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial until Day 50 were reported in this outcome measure.

    Time frame: Day 1 up to Day 50

  12. Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50

    Time frame: Day 1 up to Day 50

  13. Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 200. Here, ELISA is Enzyme-linked immunosorbent assay.

    Time frame: At Day 36

  14. Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

    GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Day 36

  15. Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

    SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Day 36

  16. Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

    SRR was defined as percentage of participants with greater than or equal to (\>=) 95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Day 36

Secondary outcomes

  1. Percentage of Participants With SAE Throughout the Trial

    Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this OM and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs throughout the trial were reported in this outcome measure.

    Time frame: Day 1 up to Day 387

  2. Percentage of Participants With AESI Throughout the Trial

    AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESI were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs throughout the trial were reported in this outcome measure.

    Time frame: Day 1 up to Day 387

  3. Percentage of Participants With MAAEs Throughout the Trial

    MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs throughout the trial were reported in this outcome measure.

    Time frame: Day 1 up to Day 387

  4. Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial

    Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to withdrawal from the trial from the day of vaccination throughout the trial were reported in this outcome measure.

    Time frame: Day 1 up to Day 387

  5. Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial

    Time frame: Day 1 up to Day 387

  6. GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 200.

    Time frame: At Days 22, 50, 202, and 387

  7. GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

    GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Days 22, 50, 202, and 387

  8. SCR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

    SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Days 22, 50, 202, and 387

  9. SRR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

    SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Days 22, 50, 202, and 387

  10. GMT of Serum Neutralizing Antibody (nAb) Titers to Wild Type Virus on Days 22, 36, 50, 202 and Day 387

    The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 20.

    Time frame: At Days 22, 36, 50, 202 and 387

  11. GMFR of Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387

    The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Days 22, 36, 50, 202 and 387

  12. SCR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387

    The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at Baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Days 22, 36, 50, 202 and 387

  13. SRR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387

    The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.

    Time frame: At Days 22, 36, 50, 202 and 387

07

Results

Posted Jun 6, 2023

Participant flow

Participants took part in the study at 2 investigative sites in Japan from 12 February 2021 to 28 March 2022.

Participant flow — Overall Study
MilestonePlaceboTAK-019 0.5 mL
Started50150
Completed4131
Not completed4619
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject04
Withdrew: Chose publicly available sars-cov-2 vaccine4614

Outcome measures

PrimaryPercentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination

Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.

Time frame:
Up to Day 7 (6 subsequent days after first vaccination on Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Injection site pain4.029.3
Tenderness4.043.3
Erythema/redness0.02.7
Induration0.03.3
Swelling0.02.7
PrimaryPercentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination

Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.

Time frame:
Up to Day 28 (6 subsequent days after second vaccination on Day 22)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Injection site pain2.050.0
Tenderness4.162.7
Erythema/redness0.015.3
Induration0.011.3
Swelling0.017.3
PrimaryPercentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination

Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.

Time frame:
Up to Day 7 (6 subsequent days after first vaccination on Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Fever0.00.0
Fatigue6.08.7
Malaise4.010.0
Myalgia4.017.3
Arthralgia0.04.7
Nausea/vomiting0.00.7
Headache2.010.7
PrimaryPercentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination

Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.

Time frame:
Up to Day 28 (6 subsequent days after second vaccination on Day 22)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Fever0.06.0
Fatigue8.220.7
Malaise6.129.3
Myalgia4.132.7
Arthralgia0.013.3
Nausea/vomiting0.05.3
Headache2.021.3
PrimaryPercentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination

Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.

Time frame:
Up to Day 21 (20 days after first vaccination on Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination8.010.0
PrimaryPercentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination

Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.

Time frame:
Up to Day 49 (27 days after second vaccination on Day 22)
Reported as:
Number · percentage of participants
Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination12.229.3
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Until Day 50

Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this outcome measure (OM) and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs until Day 50 were reported in this outcome measure.

Time frame:
Day 1 up to Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Until Day 50
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Serious Adverse Events (SAEs) Until Day 500.00.0
PrimaryPercentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50

AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESIs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs until Day 50 were reported in this outcome measure.

Time frame:
Day 1 up to Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 500.00.0
PrimaryPercentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50

MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs until Day 50 were reported in this outcome measure.

Time frame:
Day 1 up to Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 504.02.7
PrimaryPercentage of Participants With Any AE Leading to Discontinuation of Vaccination

Only any unsolicited AE leading to discontinuation of vaccination data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to discontinuation of vaccination was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to discontinuation of vaccination until Day 22 were reported in this outcome measure.

Time frame:
Day 1 up to Day 22
Reported as:
Number · percentage of participants
Percentage of Participants With Any AE Leading to Discontinuation of Vaccination
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Any AE Leading to Discontinuation of Vaccination2.00.0
PrimaryPercentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50

Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial until Day 50 were reported in this outcome measure.

Time frame:
Day 1 up to Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 500.00.0
PrimaryPercentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50
Time frame:
Day 1 up to Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 500.00.0
PrimaryGeometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 200. Here, ELISA is Enzyme-linked immunosorbent assay.

Time frame:
At Day 36
Reported as:
Geometric mean · ELISA units per mL (EU/mL)
Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36
ELISA units per mL (EU/mL)PlaceboTAK-019 0.5 mL
Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36132.3 (109.6 to 159.5)31036.8 (26837.1 to 35893.7)
PrimaryGeometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Day 36
Reported as:
Geometric mean · fold change
Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36
fold changePlaceboTAK-019 0.5 mL
Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 361.0 (1.0 to 1.1)258.8 (218.8 to 306.0)
PrimarySeroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Day 36
Reported as:
Number · percentage of participants
Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36
percentage of participantsPlaceboTAK-019 0.5 mL
Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 360.0 (0.0 to 7.3)100.0 (97.6 to 100.0)
PrimarySeroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

SRR was defined as percentage of participants with greater than or equal to (\>=) 95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Day 36
Reported as:
Number · percentage of participants
Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36
percentage of participantsPlaceboTAK-019 0.5 mL
Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 368.2 (2.3 to 19.6)100.0 (97.6 to 100.0)
SecondaryPercentage of Participants With SAE Throughout the Trial

Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this OM and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs throughout the trial were reported in this outcome measure.

Time frame:
Day 1 up to Day 387
Reported as:
Number · percentage of participants
Percentage of Participants With SAE Throughout the Trial
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With SAE Throughout the Trial2.00.0
SecondaryPercentage of Participants With AESI Throughout the Trial

AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESI were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs throughout the trial were reported in this outcome measure.

Time frame:
Day 1 up to Day 387
Reported as:
Number · percentage of participants
Percentage of Participants With AESI Throughout the Trial
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With AESI Throughout the Trial0.00.0
SecondaryPercentage of Participants With MAAEs Throughout the Trial

MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs throughout the trial were reported in this outcome measure.

Time frame:
Day 1 up to Day 387
Reported as:
Number · percentage of participants
Percentage of Participants With MAAEs Throughout the Trial
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With MAAEs Throughout the Trial6.010.7
SecondaryPercentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial

Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to withdrawal from the trial from the day of vaccination throughout the trial were reported in this outcome measure.

Time frame:
Day 1 up to Day 387
Reported as:
Number · percentage of participants
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial0.00.0
SecondaryPercentage of Participants With SARS-CoV-2 Infection Throughout the Trial
Time frame:
Day 1 up to Day 387
Reported as:
Number · percentage of participants
Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial
percentage of participantsPlaceboTAK-019 0.5 mL
Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial2.02.7
SecondaryGMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 200.

Time frame:
At Days 22, 50, 202, and 387
Reported as:
Geometric mean · EU/mL
GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
EU/mLPlaceboTAK-019 0.5 mL
Day 22144.9 (115.2 to 182.4)1390.0 (1140.8 to 1693.7)
Day 50134.7 (109.3 to 166.2)23910.8 (20737.0 to 27570.3)
Day 202851.0 (26.0 to 27800.8)4390.1 (3600.9 to 5352.3)
Day 387236.7 (15.2 to 3674.6)3461.2 (2601.5 to 4605.1)
SecondaryGMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Days 22, 50, 202, and 387
Reported as:
Geometric mean · fold change
GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
fold changePlaceboTAK-019 0.5 mL
Day 221.1 (1.0 to 1.2)11.6 (9.4 to 14.2)
Day 501.0 (1.0 to 1.1)199.1 (169.2 to 234.3)
Day 2028.5 (0.3 to 278.0)36.4 (29.8 to 44.6)
Day 3872.4 (0.2 to 36.7)27.9 (20.7 to 37.6)
SecondarySCR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Days 22, 50, 202, and 387
Reported as:
Number · percentage of participants
SCR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
percentage of participantsPlaceboTAK-019 0.5 mL
Day 226.1 (1.3 to 16.9)82.7 (75.6 to 88.4)
Day 502.0 (0.1 to 10.9)100.0 (97.6 to 100.0)
Day 20233.3 (4.3 to 77.7)97.9 (94.1 to 99.6)
Day 38725.0 (0.6 to 80.6)96.9 (92.1 to 99.1)
SecondarySRR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387

SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Days 22, 50, 202, and 387
Reported as:
Number · percentage of participants
SRR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
percentage of participantsPlaceboTAK-019 0.5 mL
Day 2210.2 (3.4 to 22.2)84.0 (77.1 to 89.5)
Day 5012.2 (4.6 to 24.8)100.0 (97.6 to 100.0)
Day 20233.3 (4.3 to 77.7)97.9 (94.1 to 99.6)
Day 38725.0 (0.6 to 80.6)96.9 (92.1 to 99.1)
SecondaryGMT of Serum Neutralizing Antibody (nAb) Titers to Wild Type Virus on Days 22, 36, 50, 202 and Day 387

The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 20.

Time frame:
At Days 22, 36, 50, 202 and 387
Reported as:
Geometric mean · 1 per dilution
GMT of Serum Neutralizing Antibody (nAb) Titers to Wild Type Virus on Days 22, 36, 50, 202 and Day 387
1 per dilutionPlaceboTAK-019 0.5 mL
Day 2210.4 (9.9 to 10.9)50.2 (41.2 to 61.0)
Day 3610.4 (9.9 to 10.9)884.4 (749.0 to 1044.4)
Day 5010.4 (9.9 to 10.9)509.5 (422.5 to 614.6)
Day 20250.4 (3.6 to 698.8)65.5 (53.4 to 80.4)
Day 38714.1 (4.7 to 42.6)65.7 (49.0 to 88.1)
SecondaryGMFR of Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387

The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Days 22, 36, 50, 202 and 387
Reported as:
Geometric mean · fold change
GMFR of Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387
fold changePlaceboTAK-019 0.5 mL
Day 221.0 (1.0 to 1.1)5.0 (4.1 to 6.1)
Day 361.0 (1.0 to 1.1)88.0 (74.5 to 104.0)
Day 501.0 (1.0 to 1.1)50.7 (42.0 to 61.2)
Day 2025.0 (0.4 to 69.9)6.5 (5.3 to 8.0)
Day 3871.4 (0.5 to 4.3)6.5 (4.9 to 8.7)
SecondarySCR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387

The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at Baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Days 22, 36, 50, 202 and 387
Reported as:
Number · percentage of participants
SCR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387
percentage of participantsPlaceboTAK-019 0.5 mL
Day 220.0 (0.0 to 7.3)67.3 (59.2 to 74.8)
Day 360.0 (0.0 to 7.3)99.3 (96.3 to 100.0)
Day 500.0 (0.0 to 7.3)98.0 (94.2 to 99.6)
Day 20233.3 (4.3 to 77.7)76.0 (68.3 to 82.7)
Day 38725.0 (0.6 to 80.6)70.9 (62.1 to 78.6)
SecondarySRR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387

The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.

Time frame:
At Days 22, 36, 50, 202 and 387
Reported as:
Number · percentage of participants
SRR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387
percentage of participantsPlaceboTAK-019 0.5 mL
Day 22100.0 (92.7 to 100.0)100.0 (97.6 to 100.0)
Day 36100.0 (92.7 to 100.0)100.0 (97.6 to 100.0)
Day 50100.0 (92.7 to 100.0)100.0 (97.6 to 100.0)
Day 202100.0 (54.1 to 100.0)100.0 (97.5 to 100.0)
Day 387100.0 (39.8 to 100.0)100.0 (97.1 to 100.0)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are AEs that started after the first vaccination on Day 1 up to 365 days after the second vaccination on Day 22 (Day 387). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/50 (0%)1/50 (2%)11/50 (22%)
TAK-0190/150 (0%)0/150 (0%)124/150 (82.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboTAK-019
COVID-19Infections and infestations1/500/150
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboTAK-019
TendernessGeneral disorders3/50100/150
Injection site painGeneral disorders3/5088/150
MyalgiaMusculoskeletal and connective tissue disorders4/5056/150
MalaiseGeneral disorders6/5050/150
HeadacheNervous system disorders2/5041/150
FatigueGeneral disorders7/5039/150
SwellingGeneral disorders0/5027/150
Injection site pruritusGeneral disorders0/5026/150
Vaccination site erythemaGeneral disorders0/5026/150
ArthralgiaMusculoskeletal and connective tissue disorders1/5024/150

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of the treatment.

Age, Continuous
Age, Continuous(years)PlaceboTAK-019 0.5 mLTotal
Mean50.8 ± 16.4252.6 ± 15.8052.2 ± 15.93
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTAK-019 0.5 mLTotal
Female216586
Male2985114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTAK-019 0.5 mLTotal
Japanese50150200
Region of Enrollment
Region of Enrollment(Participants)PlaceboTAK-019 0.5 mLTotal
Japan50150200
Weight
Weight(kilogram (kg))PlaceboTAK-019 0.5 mLTotal
Mean61.73 ± 11.80662.94 ± 10.48562.64 ± 10.813
Height
Height(centimeter (cm))PlaceboTAK-019 0.5 mLTotal
Mean164.00 ± 9.157164.10 ± 8.596164.08 ± 8.716
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))PlaceboTAK-019 0.5 mLTotal
Mean22.80 ± 2.86523.29 ± 2.85023.17 ± 2.854
08

Study locations

2 sites
  • Sumida Hospital
    Sumida-ku, Tokyo, Japan
  • Nishi Kumamoto Hospital
    Kumamoto, Japan
09

References and documents

Publications

  • Masuda T, Murakami K, Sugiura K, Sakui S, Schuring RP, Mori M. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. Vaccine. 2022 May 26;40(24):3380-3388. doi: 10.1016/j.vaccine.2022.04.035. Epub 2022 Apr 29. PubMed 35501178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2022, 13 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

Of 11 phase 1/2 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 5 months of starting (the median); a quarter within 3 and three quarters within 13. This study's 13 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2021
First posted
Jan 15, 2021
StartActual
Feb 12, 2021
Primary completionActual
Mar 28, 2022
CompletionActual
Mar 28, 2022
Results first posted
Jun 6, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04712110
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Feb 12, 2021
Primary completion
Mar 28, 2022
Completion
Mar 28, 2022
Results posted
Jun 6, 2023
Last update
Jun 6, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion